Arrowhead Pharmaceuticals, Inc.

Informe acción NasdaqGS:ARWR

Capitalización de mercado: US$2.3b

Arrowhead Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de Arrowhead Pharmaceuticals es Chris Anzalone , nombrado en Dec 2007, tiene una permanencia de 16.92 años. compensación anual total es $9.92M, compuesta por 9.1% salario y 90.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.99% de las acciones de la empresa, por valor de $67.91M. La antigüedad media del equipo directivo y de la junta directiva es de 6.4 años y 14 años, respectivamente.

Información clave

Chris Anzalone

Chief Executive Officer (CEO)

US$9.9m

Compensación total

Porcentaje del salario del CEO9.1%
Permanencia del CEO16.9yrs
Participación del CEO3.0%
Permanencia media de la dirección6.4yrs
Promedio de permanencia en la Junta Directiva14yrs

Actualizaciones recientes de la dirección

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Recent updates

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Oct 04
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 26

Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jun 12
Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: Hoping Something Sticks

May 27

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

May 21
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

May 17

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Apr 03
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Mar 30

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19
Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25
Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10
Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Anzalone en comparación con los beneficios de Arrowhead Pharmaceuticals?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

-US$539m

Mar 31 2024n/an/a

-US$471m

Dec 31 2023n/an/a

-US$297m

Sep 30 2023US$10mUS$903k

-US$205m

Jun 30 2023n/an/a

-US$181m

Mar 31 2023n/an/a

-US$150m

Dec 31 2022n/an/a

-US$155m

Sep 30 2022US$12mUS$863k

-US$176m

Jun 30 2022n/an/a

-US$154m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$183m

Sep 30 2021US$25mUS$837k

-US$141m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020n/an/a

-US$103m

Sep 30 2020US$14mUS$786k

-US$85m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

US$10m

Dec 31 2019n/an/a

US$53m

Sep 30 2019US$2mUS$674k

US$68m

Jun 30 2019n/an/a

US$46m

Mar 31 2019n/an/a

US$10m

Dec 31 2018n/an/a

-US$29m

Sep 30 2018US$2mUS$643k

-US$54m

Compensación vs. Mercado: La compensación total de Chris($USD9.92M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.43M).

Compensación vs. Ingresos: La compensación de Chris ha sido consistente con los resultados de la empresa en el último año.


CEO

Chris Anzalone (55 yo)

16.9yrs

Permanencia

US$9,918,093

Compensación

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Christopher Anzalone
CEO, President & Director16.9yrsUS$9.92m2.99%
$ 67.9m
Kenneth Myszkowski
Chief Financial Officer14.8yrsUS$3.12m0.19%
$ 4.3m
Patrick O'Brien
COO, General Counsel & Secretary9.9yrsUS$3.31m0.23%
$ 5.2m
James Hamilton
Chief of Discovery & Translational Medicineno dataUS$3.05m0.16%
$ 3.7m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datasin datossin datos
Vincent Anzalone
Head of Investor Relations & VPno datasin datossin datos
Howard Lovy
Director of Communications19.3yrssin datossin datos
Bruce Given
Chief Medical Scientistless than a yearUS$16.34msin datos
Mark Seefeld
Head of Toxicology & VPno datasin datossin datos
Aaron Tan
Head of Tax2.8yrssin datossin datos
Andy Davis
SVP of Cardiovascular & Head of Metabolic Franchiseno datasin datossin datos
Nadia Meshkova
VP & Treasurer2.8yrssin datossin datos

6.4yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ARWR es experimentado (6.4 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Christopher Anzalone
CEO, President & Director16.9yrsUS$9.92m2.99%
$ 67.9m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datasin datossin datos
Douglass Given
Chairman of the Board14yrsUS$474.60k0.11%
$ 2.6m
Michael Perry
Independent Lead Director12.9yrsUS$459.60k0.074%
$ 1.7m
William Waddill
Independent Director6.8yrsUS$469.60k0.026%
$ 601.1k
Ching-Lung Lai
Member of Hepatitis B Clinical Advisory Boardno datasin datossin datos
Robert Gish
Chairman of Hepatitis B Clinical Advisory Boardno datasin datossin datos
Mauro Ferrari
Independent Director14.3yrsUS$459.60k0.037%
$ 837.0k
Jeffrey Teckman
Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Boardno datasin datossin datos
Stephen Locarnini
Member of Hepatitis B Clinical Advisory Boardno datasin datossin datos
Johnson Lau
Member of Hepatitis B Clinical Advisory Boardno datasin datossin datos
Carlo Ferrari
Member of Hepatitis B Clinical Advisory Boardno datasin datossin datos

14.0yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de ARWR son experimentados ( 14 años antigüedad media).